Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683722 · ClinicalTrials.gov registry record · Phase 2
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00683722 is a Phase 2 study that has completed, run by Mesoblast. The registered enrollment target is 62 participants.
The verdict
NCT00683722, a Phase 2 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo
- DRUG Prochymal™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-03-20 |
| Est. Completion | 2010-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683722
The ClinicalTrials.gov registry entry for NCT00683722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00683722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683722 about?
NCT00683722 is a clinical study titled "PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00683722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-03-20. Estimated completion is 2010-08-24.
What interventions are being tested in trial NCT00683722?
The interventions under investigation include: Placebo (DRUG), Prochymal™ (DRUG).
Who is sponsoring clinical trial NCT00683722?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.